Enllaços d'accés:
CONTINGUT
Destacados
- Actiu
CUTHIVAC Cutaneous HIV Vaccination
The CUT’HIVAC project is an innovative needle-free vaccination strategy across the skin to combat HIV and other infectious diseases.
Funded by the European...
Entitat finançadora: European Comission
Entitat(s) participant(s): Universite Pierre et Marie Curie, University of Regensburg, FIT Biotech Oy Ltd, CHARITE, St George’s University of London, MRC Medical Research Council, IMPACTA, Centre National de la Recherche Scientifique, INSERM, Instituto Nacional de Saúde, GENEART AG, NOVAMEN
Data: 01/01/2010
Investigador(s) responsable(s): Christian Brander
- Actiu
Natural prevalence of HCV variants with decreased sensitivity to NS3/4A protease inhibitors in HIV-1 co-infected patients treated with interferon (peg-INF) plus ribavirin (RBV)
Entitat finançadora: Merck Sharp & Dohme
Entitat(s) participant(s): Fundació IrsiCaixa
Data: 01/10/2009
- Actiu
Collaborative HIV and Anti-HIV Drug Resistance Network
CHAIN - 223131
Entitat finançadora: European Community Framework –Network of excellence
Entitat(s) participant(s): Fundació IrsiCaixa
Data: 01/04/2009
- Actiu
HIV Coevolution and Drug Resistance
Support for training and career development of researchers (Marie Curie). European Re-integration Grants (ERG) - GRANT AGREEMENT No 238885.
Entitat finançadora: European Community, 7th Framework Programme
Entitat(s) participant(s): Fundació IrsiCaixa
Data: 01/04/2009
- Actiu
Mucosal Nano Vaccine Candidate for HIV - Munanovac
STREP - LSHP-CT-2006-037200
Entitat finançadora: Comissió Europea
Entitat(s) participant(s):
Data: 01/01/2009
